BR0113293A - Formulação oral com fundição rápida de um inibidor de ciclo-oxigenase 2 - Google Patents
Formulação oral com fundição rápida de um inibidor de ciclo-oxigenase 2Info
- Publication number
- BR0113293A BR0113293A BR0113293-8A BR0113293A BR0113293A BR 0113293 A BR0113293 A BR 0113293A BR 0113293 A BR0113293 A BR 0113293A BR 0113293 A BR0113293 A BR 0113293A
- Authority
- BR
- Brazil
- Prior art keywords
- granules
- blending
- oral formulation
- cyclooxygenase inhibitor
- fast melt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"FORMULAçãO ORAL COM FUNDIçãO RáPIDA DE UM INIBIDOR DE CICLO-OXIGENASE 2". Fornece-se um processo para preparar uma composição oral de fundição rápida de uma droga inibidora seletiva de ciclo-oxigenase 2, o processo compreendendo: (a) uma etapa de granular a úmido a droga junto com um agente ligante compreendendo um sacarídeo de alta moldabilidade, e (b) uma etapa de mesclar com a droga um sacarídeo de baixa moldabilidade, onde as etapas (a) e (b) ocorrem em qualquer ordem ou simultaneamente, para resultar na formação de grânulos. O processo incorpora opcionalmente um meio para inibir a aglomeração da droga, como por exemplo, a adição de um agente umectante. Opcionalmente, o processo compreende ainda (c) uma etapa de misturar os ditos grânulos com pelo menos um lubrificante, um agente edulcorante e um agente aromatizante, para formar uma mistura para comprimidos, e (d) uma etapa de comprimir a mistura para comprimidos, a fim de formar comprimidos de fundição rápida. Fornece-se também uma composição preparada por este processo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22634700P | 2000-08-18 | 2000-08-18 | |
PCT/US2001/025803 WO2002015885A2 (en) | 2000-08-18 | 2001-08-17 | Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113293A true BR0113293A (pt) | 2003-06-10 |
Family
ID=22848576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0113293-8A BR0113293A (pt) | 2000-08-18 | 2001-08-17 | Formulação oral com fundição rápida de um inibidor de ciclo-oxigenase 2 |
Country Status (20)
Country | Link |
---|---|
US (1) | US20020049233A1 (pt) |
EP (2) | EP1309316A2 (pt) |
JP (2) | JP2004512274A (pt) |
KR (1) | KR20030045035A (pt) |
CN (1) | CN1638739A (pt) |
AT (1) | ATE374599T1 (pt) |
AU (3) | AU2001286530B2 (pt) |
BR (1) | BR0113293A (pt) |
CA (2) | CA2418730A1 (pt) |
CZ (1) | CZ2003422A3 (pt) |
DE (1) | DE60130801T2 (pt) |
DK (1) | DK1355631T3 (pt) |
ES (1) | ES2292614T3 (pt) |
IL (1) | IL154386A0 (pt) |
MX (2) | MXPA03001346A (pt) |
NO (1) | NO20030727L (pt) |
NZ (2) | NZ524115A (pt) |
PL (1) | PL360704A1 (pt) |
PT (1) | PT1355631E (pt) |
WO (2) | WO2002015885A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002303577B2 (en) * | 2001-05-04 | 2006-06-08 | Merck & Co., Inc. | Method and compositions for treating migraines |
EP1490035A1 (en) * | 2001-09-26 | 2004-12-29 | Pharmacia Corporation | Intraorally disintegrating valdecoxib compositions |
MXPA04003404A (es) * | 2001-10-10 | 2004-06-18 | Pharmacia Corp | Composiciones de valdecoxib de disgregacion intraoral preparadas mediante un procedimiento de desecacion por pulverizacion. |
EP1446088A2 (en) * | 2001-11-07 | 2004-08-18 | Pharmacia Corporation | Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US20080095850A1 (en) * | 2004-11-04 | 2008-04-24 | Ho Jennifer S | Process for Granulating Particles |
JP4945917B2 (ja) * | 2005-01-19 | 2012-06-06 | 大正製薬株式会社 | 薬物含有コーティング用核粒子 |
EP3782655A1 (en) * | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
US20070098804A1 (en) * | 2005-08-29 | 2007-05-03 | Judith Aronhime | Solid particulate tadalafil having a bimodal particle size distribution |
US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
CN101340894B (zh) * | 2005-12-23 | 2012-12-12 | 力奇制药公司 | 爆裂小丸 |
US20100233272A1 (en) * | 2007-11-15 | 2010-09-16 | Leah Elizabeth Appel | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
CA2866683A1 (en) | 2012-03-07 | 2013-09-12 | Amicus Therapeutics, Inc. | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
CN104027319A (zh) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | 一种塞来昔布分散片及其制备方法 |
EA038986B1 (ru) | 2014-09-30 | 2021-11-18 | Амикус Терапьютикс, Инк. | Высокоактивная кислая альфа-глюкозидаза с повышенным содержанием углеводов |
EA201891507A1 (ru) | 2015-12-30 | 2018-12-28 | Амикус Терапьютикс, Инк. | Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе |
WO2017173060A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
IL295551A (en) | 2016-03-30 | 2022-10-01 | Amicus Therapeutics Inc | A method for selecting recombinant proteins with a high amount of mannose-6-phosphate |
US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
CN108576205B (zh) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种草莓联合干燥的处理方法 |
EP3883562A4 (en) | 2018-11-21 | 2022-08-03 | Tremeau Pharmaceuticals, Inc. | PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING |
JP2020183359A (ja) * | 2019-05-09 | 2020-11-12 | 日医工株式会社 | セレコキシブ含有医薬組成物 |
US10945992B1 (en) | 2019-11-13 | 2021-03-16 | Tremeau Pharmaceuticals, Inc. | Dosage forms of rofecoxib and related methods |
US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69532110T2 (de) * | 1994-01-31 | 2004-09-09 | Yamanouchi Pharmaceutical Co., Ltd. | Intraoral löslicher formpressling und verfahren zu seiner herstellung |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
ZA964928B (en) * | 1995-06-13 | 1997-12-10 | American Home Prod | Oral formulations of S(+)-etodolac. |
JPH11512754A (ja) * | 1996-05-17 | 1999-11-02 | メルク エンド カンパニー インコーポレーテッド | シクロオキシゲナーゼ―2媒介疾患の一日一回治療用組成物 |
US5958453A (en) * | 1996-10-31 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility |
IT1293764B1 (it) * | 1997-07-23 | 1999-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
BR0008059A (pt) * | 1999-12-08 | 2002-03-26 | Pharmacia Corp | Composições de valdecoxib |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
PL363771A1 (en) * | 2001-02-27 | 2004-11-29 | Ranbaxy Laboratories Limited | Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors |
-
2001
- 2001-08-13 CN CNA018140920A patent/CN1638739A/zh active Pending
- 2001-08-17 ES ES01965984T patent/ES2292614T3/es not_active Expired - Lifetime
- 2001-08-17 NZ NZ524115A patent/NZ524115A/en unknown
- 2001-08-17 WO PCT/US2001/025803 patent/WO2002015885A2/en active IP Right Grant
- 2001-08-17 AU AU2001286530A patent/AU2001286530B2/en not_active Ceased
- 2001-08-17 CZ CZ2003422A patent/CZ2003422A3/cs unknown
- 2001-08-17 MX MXPA03001346A patent/MXPA03001346A/es not_active Application Discontinuation
- 2001-08-17 PT PT01965984T patent/PT1355631E/pt unknown
- 2001-08-17 BR BR0113293-8A patent/BR0113293A/pt not_active Application Discontinuation
- 2001-08-17 WO PCT/US2001/025834 patent/WO2002015886A2/en not_active Application Discontinuation
- 2001-08-17 KR KR10-2003-7002392A patent/KR20030045035A/ko not_active Application Discontinuation
- 2001-08-17 PL PL36070401A patent/PL360704A1/xx not_active Application Discontinuation
- 2001-08-17 JP JP2002520807A patent/JP2004512274A/ja not_active Withdrawn
- 2001-08-17 AU AU2001286533A patent/AU2001286533A1/en not_active Abandoned
- 2001-08-17 EP EP01965987A patent/EP1309316A2/en not_active Withdrawn
- 2001-08-17 EP EP01965984A patent/EP1355631B1/en not_active Expired - Lifetime
- 2001-08-17 AU AU8653001A patent/AU8653001A/xx active Pending
- 2001-08-17 JP JP2002520808A patent/JP2004506681A/ja not_active Withdrawn
- 2001-08-17 DE DE60130801T patent/DE60130801T2/de not_active Expired - Fee Related
- 2001-08-17 NZ NZ524123A patent/NZ524123A/en unknown
- 2001-08-17 US US09/932,500 patent/US20020049233A1/en not_active Abandoned
- 2001-08-17 CA CA002418730A patent/CA2418730A1/en not_active Abandoned
- 2001-08-17 AT AT01965984T patent/ATE374599T1/de not_active IP Right Cessation
- 2001-08-17 DK DK01965984T patent/DK1355631T3/da active
- 2001-08-17 MX MXPA03001408A patent/MXPA03001408A/es not_active Application Discontinuation
- 2001-08-17 IL IL15438601A patent/IL154386A0/xx unknown
- 2001-08-17 CA CA002420190A patent/CA2420190A1/en not_active Abandoned
-
2003
- 2003-02-14 NO NO20030727A patent/NO20030727L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2002015885A2 (en) | 2002-02-28 |
MXPA03001408A (es) | 2005-06-30 |
KR20030045035A (ko) | 2003-06-09 |
ATE374599T1 (de) | 2007-10-15 |
AU8653001A (en) | 2002-03-04 |
JP2004512274A (ja) | 2004-04-22 |
IL154386A0 (en) | 2003-09-17 |
NO20030727D0 (no) | 2003-02-14 |
AU2001286533A1 (en) | 2002-03-04 |
EP1355631A2 (en) | 2003-10-29 |
DE60130801T2 (de) | 2008-06-26 |
AU2001286530B2 (en) | 2007-01-25 |
NO20030727L (no) | 2003-03-24 |
CA2420190A1 (en) | 2002-02-28 |
WO2002015886A2 (en) | 2002-02-28 |
ES2292614T3 (es) | 2008-03-16 |
PL360704A1 (en) | 2004-09-20 |
NZ524123A (en) | 2005-02-25 |
NZ524115A (en) | 2004-10-29 |
WO2002015886A3 (en) | 2002-07-25 |
US20020049233A1 (en) | 2002-04-25 |
MXPA03001346A (es) | 2003-06-06 |
EP1309316A2 (en) | 2003-05-14 |
CN1638739A (zh) | 2005-07-13 |
WO2002015885A3 (en) | 2003-08-28 |
DE60130801D1 (de) | 2007-11-15 |
PT1355631E (pt) | 2007-11-29 |
EP1355631B1 (en) | 2007-10-03 |
DK1355631T3 (da) | 2008-02-04 |
CA2418730A1 (en) | 2002-02-28 |
JP2004506681A (ja) | 2004-03-04 |
CZ2003422A3 (cs) | 2003-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113293A (pt) | Formulação oral com fundição rápida de um inibidor de ciclo-oxigenase 2 | |
TWI256305B (en) | Oral fast-melt pharmaceutical composition of a cyclooxygenase-2 inhibitor and process for preparing the same | |
NO20003196D0 (no) | Umiddelbart smeltende doseringsformulering | |
AU3752501A (en) | Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same | |
DK1150961T3 (da) | Pyrazolcarboxylsyrederivater, fremstilling af disse og farmaceutiske præparater indeholdende disse | |
AU2001237525A1 (en) | Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same | |
MA27589A1 (fr) | Composes a base d'indazole, compositions pharmaceutiques et methodes pour modifier legerement ou inhiber la proliferation de cellules | |
CA2284051A1 (en) | Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates | |
MA26968A1 (fr) | Compositions pharmaceutiques contenant du maleate d'amlodipine. | |
AU2001237526A1 (en) | Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof | |
ATE460921T1 (de) | Medikamenthaltige zusammensetzung in aerosolform | |
HUP0203836A3 (en) | 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use | |
DK199900554A (da) | Paroxetinsalte, fremgangsmåde til fremstilling deraf, farmaceutiske præparater omfattende disse og anvendelser deraf | |
HK1064671A1 (en) | Process for making amlodipine maleate, the amlodipine maleate prepared, the pharmaceutical composition and the use thereof | |
DK1334717T3 (da) | Farmaceutiske sammensætninger til oral og topisk administrering | |
IL151912A0 (en) | Pyrolidine derivatives, their preparation and pharmaceutical compositions containing them | |
HUP0301080A3 (en) | Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives, process for their preparation and pharmaceutical compositions containing them | |
ATE222586T1 (de) | Benzolsulfonamidderivate und verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
ATE266404T1 (de) | Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält | |
WO1999047172A3 (en) | Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes | |
AR034435A1 (es) | Agentes terapeuticos. | |
WO2003013441A3 (en) | Levothyroxine compositions and methods | |
ATE358677T1 (de) | Benzo(e)(1,4)oxazino(3,2-g)isoindol-derivate, verfahren zu ihrer herstellung unddiese enthaltende pharmazeutische zusammensetzungen | |
WO2004087648A3 (en) | Stabilized phenytoin containing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |